Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks palbociclib use in canadian breast cancer patients

NCT ID NCT06003114

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study observes how Canadian women with a specific type of advanced breast cancer (HR+/HER2-) use the drug palbociclib (Ibrance) as their first treatment. Researchers will measure how long patients stay on the drug and look at treatment patterns in real-world settings, outside of a controlled clinical trial. The goal is to better understand how this medication is actually used in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
palbociclib (Ibrance)
What this could lead to
If successful, this study could reveal how well palbociclib works outside of clinical trials, helping doctors optimize treatment for women with this type of breast cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

472 people

The number who actually took part.

Started

Oct 2023

Finished

Feb 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Treatment of Canadian women patients on palbociclib with HR+/HER2- metastatic breast cancer

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Received at least one cycle of palbociclib as first line therapy for metastatic breast cancer between 01 January 2016 and 31 December 2022 * Histologically confirmed HR+/HER2- metastatic breast cancer * Minimum of 3 months available follow-up on palbociclib Exclusion Criteria: * Received a different CDK4/6 inhibitor before palbociclib in the first line * Received other systemic therapy, including hormone therapy, 15-60 days prior to initiation of palbociclib * Invalid or incomplete records (more specifically, complete duration of treatment on palbociclib, endocrine therapy or LHRH) * Death date recorded on or before the date of index date

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Alberta Health Services

    Edmonton, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.